The market for chondrosarcoma is projected to experience growth between 2026 and 2036 due to factors such as enhanced diagnostic methods, advancements in treatment options, heightened awareness, and the introduction of new therapies like Ozekibart (INBRX-109) by Inhibrx Biosciences and TIBSOVO (ivosidenib) by Servier. These developments are expected to drive the market forward, leading to increased opportunities and potential for advancements in the treatment of chondrosarcoma.